Names that move as a basket.

MI450/Helios rack-scale plus EPYC agentic-CPU narrative drove ATHs near $561.80 (7/1), but the July target cluster ($600 BNP, $620 BofA, $725 high) is arriving into a falling tape 20-day MA lost 7/8, chip-led Nasdaq selloff 7/17, sentiment…

Enterprise AI-server rebuild intact fundamentally (+757% YoY AI-server revenue), but the tape broke: 2026-07-15 reversed 13% from near-record high to $397 as the memory complex and SMCI sold off. Lower high vs the $475.40 ATH, momentum…

AI-server and enterprise-networking pivot is real at the theme level, but HPE's own chart broke: the record +25% Q2 FY26 blowoff (2026-06-02, ATH $64.25) fully round-tripped, the ~$48 pre-print shelf failed (last observed close $43.71 on…

NetApp's first genuine AI re-rating (2026-05-28 Q4 print) is now digesting the ~35% gap to $192.83 has round-tripped to the ~$150 breakout-retest zone by 2026-06-26. FY27 revenue guided only +8%, no company binary until ~late-August Q1.…

Maturing AI-storage supercycle with sell-side still chasing: Wells Fargo upgrade to Overweight $1,100 (7/10) and Citi Street-high $1,240 (7/13). But the DRAM ETF is down ~30% and Seagate's Q4 FY26 print ~2026-07-22 is a binary about two…

Silicon-photonics pivot re-rated the ADR ~3x, but the July blowoff to $28.96 round-tripped -26% to $21.25 in days while sell-side finally upgraded (Macquarie Outperform 2026-07-14) late-stage distribution behaviour. The 2026-07-29 Q2 print…

Parabola fully broken: ~$101.58 on 2026-07-18 is -57% from the $233.67 high, and the $150 shelf that defined the uptrend is long gone. Fundamentals still accelerating (FY26 guide >$1.1B) but insiders sold ~$17M into the top and the…

InP substrate supplier one layer upstream of AI optical interconnect fundamentals still accelerating on the 7/2 Coherent master supply deal ($22.29M prepay) and $100M backlog, but the tape has round-tripped >50% off the $143 ATH toward the…

Neocloud de-rating is confirming, not contested: Meta's reported ~$10B Anthropic compute deal (7/18) turns the disintermediation threat into a signed transaction, shares are -30% in a month, and desks are cutting (Mizuho $100, Macquarie…

Narrative flipped from capex-defense to compute-monetization: a reported $10B/2yr Anthropic data-center lease (7/17-7/18) turns Meta's buildout into contracted external revenue, confirmed by NBIS and IREN derating on "Meta Compute"…

The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the…

Legacy crypto-financials name re-rating to AI-data-center landlord: Phase I ~200MW at the Helios campus was delivered to CoreWeave on 2026-07-06, turning the ~$4.5B/15-yr lease from promise into live contracted revenue while shares still…

Bitcoin-miner-to-AI-datacenter-landlord re-rate is now financed fact ($4.25B IG notes 6/4, ~$16.8B contracted backlog), but the momentum leg rolled from ~$127 to ~$105 as peers WULF/IREN captured the marquee Anthropic tenant deals (7/6)…

Neocloud narrative has inverted: Meta Compute (7/1 Bloomberg) turned the biggest customer into the biggest competitor, and NBIS is -38% from its 6/18 close high of $286.69 despite a $1B Reflection AI deal and a $775M non-dilutive…

The data-center re-rating already failed: QCOM spiked to a 52-week high of $259.92 on the ~2026-06-24 Investor Day $15B-by-2029 guide, then gave back ~34% in 17 sessions to $171.78 as Hold downgrades and Apple modem-attrition math…

BTC-to-AI-landlord re-rating is structurally intact AMD $311M/50MW Rockdale lease, $33.2M Q1 data-center revenue, Citi reiterated Buy/PT $28 on 2026-07-08 but the miner complex rolled over on a Q2 crypto rout and "fresh AI-pivot headwinds"…

Solar/BESS EBOS name re-rated as a 2nd-order AI-datacenter-power play on a record $758M Q1 backlog and the multi-GW ON.energy deal; price reclaimed the $10 pivot but consensus PT sits at spot (~$10.63 vs $10.02), so the confirmed…

Analog cyclical-trough plus the $1.5B Empower AI-power option fired and fully repriced in one week around the ~2026-05-20 Q2 print; nine weeks on, four more target raises (Cantor $550, Keybanc $525) are sell-side catch-up on a published…

Frac-sand legacy name pivoting to behind-the-meter gas power for AI data centers, but the post-Caterpillar re-rating has round-tripped: shares lost the ~$15 breakout base to $14.39 (7/10), no new PPA since 4/1, and a Russell growth-index…

Listed pure-play gas EPC on the AI data-center power buildout theme ACCELERATING ($2.8B backlog, 4.1+ GW gas pipeline) but the stock blew off to an $805.75 ATH and has round-tripped the entire Q1 pop, closing $630.32 on 2026-07-10 and…

Analog/power-IC re-rate on the AI data-center power-attach story stays analyst-confirmed Mizuho PT $67 (6/29), TD Cowen $70 (6/22) after the record ~$60 print but the stock sits ~10% above the ~$54 consensus fair value, ~2x GF Value, is…

AWS reacceleration (+28% YoY in Q1, 15-quarter high) has not converted into tape shares ~$245 vs the May high of $278.56, pinned on the 50-day with megacap flow rotating to IJR/IJH/RSP. KeyBanc lifted its target to $335 on 2026-07-16…

Post-parabola dormancy: the April–May "second-order AI power-semi" re-rate (~3x to $54.34) is fully realized, priced above the $30.50 consensus PT, with no fresh AOSL catalyst in five-plus weeks. Next binary is the ~early-August FY26-Q4…

Post-TrojAI AI-security re-rate still accelerating but now MATURING and extended: ATEN at all-time highs (~$36.30, June 30 close $37.36) trading ~15–20% above the blended $30–32 consensus and above every desk but the lone $45 bull. Aug 5…

Tape flipped since early July: BBY broke to a fresh 52-week high $87.35 (~$85.41 on 2026-07-17, +27.6% YTD) on RGB-LED TV exclusivity plus an AI-PC/MacBook refresh cycle. But price sits ~8% above the $79.15 consensus target while Loop…

On-site SOFC power for AI datacenters is ACCELERATING and cluster-confirmed (Oracle 2.8GW, Nebius $2.6B, FERC large-load order, record $328.91 on 6/18), but two July short reports Hunterbrook (7/8) on China-free supply, Crossroads (7/9) on…

Broken wrapper on an accelerating underlying: WhiteFiber (WYFI, ~70% owned) held $38.50 on its 7/9 cross-datacenter networking milestone, but BTBT de-rated to $1.69 toward its $1.25 52-week low blowing the SOTP discount out to ~54% (the…

Spring miner-to-AI re-rate has fully unwound: BTDR lost the $15 shelf to $12.56 (2026-07-09) as AI-cloud ARR plateaued at ~$69M for a 2nd month. A signed-but-not-effective Tydal colocation lease (2026-06-29) and a $36M Nevada plant are the…

Capital-light auto marketplace compounding per-share via a 29%-of-float buyback and steady ~15% marketplace growth, but the theme is MATURING, growth is decelerating (Q2 guide +11-14% vs Q1 +15%), and the 2026-08-06 print is a binary with…

Post-blowoff digestion: after a ~4x run to a $94.31 ATH (2026-06-29), a $73 secondary (4.6M shares, ~$336M, closed 06-26) capped the parabola and CDNL now trades below the deal price near $68 under its $63 average analyst target.…

Second-order AI-server reseller whose ~37% recovery off the $97 low has stalled: a mid-July push to $144 round-tripped to $133 by 2026-07-17, right in the fairway of the ~$145 consensus target. The re-rate (JPM, MS $170, Citi $145) is…

Fallen drug-development software name grafting an NVIDIA agentic-AI headline onto a broken tape: May 11 FY26 guidance cut ($0.35–0.41 EPS), CFO exit July 14, and a faded July NVIDIA pop leave price ~$6.90 rolled over below all MAs near…

AI-compute test picks-&-shovels re-rate (Eclipse xPU handlers + Neon HBM inspection) is now a broad sell-side chase three PT raises in a month to $65–80 (TD Cowen $80, Baird $65, Stifel $70) with the stock near its $70.47 ATH after…

Cyber/AI-security demand still accelerating, but CRWD's own tape isn't confirming it: the 2026-06-03 sell-the-news repair rolled back over in July, shares slipping despite split-adjusted PT hikes ($172–$235), and the 4-for-1 split (7/2)…

The AI-server/auto power-content re-rate that carried DIOD to a ~$126 all-time high (June 18) has round-tripped: a double-top, an analyst downgrade, more insider selling and a sector-wide semi selloff pushed it to ~$96 by July 10, through…

Railcar-inspection shell re-rated into an AI data-center/edge-compute + behind-the-meter power operator. July-7 Nistar 2 MW MSA and Russell 2000 inclusion rebuild the story above the $9.50 secondary floor, but structure stays broken below…

Closed-end SpaceX proxy whose entire bull case the pre-IPO scarcity premium is now dead: SpaceX trades publicly (SPCX, $135 IPO 2026-06-12, ran to $225, back near ~$145 lows by 2026-07-10). DXYZ's premium has collapsed from ~151% (May)…

IQ SST AI-data-center pivot (announced 2026-04-28) that drove a spring squeeze has stalled stock de-rated ~16% in a month to ~$45 (2026-07-09), sell-side uniformly neutral with PTs on top of price (Susquehanna $45, 2026-07-10), and SST…

Legacy campus-networking name re-rating ~+140% off Feb lows on the Platform ONE / Agent ONE AI-NetOps story plus SaaS ARR +29% YoY; theme still ACCELERATING but spot ($33.71, 07-10) has run through consensus PT $29.06 into the June bull…

Data-center-power narrative intact, but the June re-rating just met a $225M equity raise (10.71M sh at $21.00, July 8) that capped the move; a Siemens design/supply partnership (July 9) stabilized the tape, yet a fresh entry near $21…

Legacy-CCaaS AI pivot staged a sharp V-recovery: +29% off the $19.70 June swing low to $25.42, reclaiming the broken $22 shelf on a 2026-06-23 next-gen Voice AI Agents launch and an AI-first leadership overhaul. Now pressing the $26.26…

AI-manufacturing re-acceleration: the 2026-07-09 Cerebras CS-3 production expansion is the first company-specific bid since the S&P-inclusion +6% pop round-tripped to ~$147, refreshing the data-center power/EMS narrative into the ~07-29 Q1…

Second secondary in five weeks ~43.6M shares at $49 on July 2, now including company primary dilution confirms the recurring-supply pattern and dragged the stock from its $65.56 June-4 ATH back to the offering line. The…

July re-stacked a capped bull cluster Deutsche Bank Buy $272 (07-07), Morgan Stanley OW $245 (07-09), Susquehanna Positive $270 (07-10) yet every target sits at/below the June $305–310 high, and a third "10-year returns" retail piece…

Cyber-software leader still pinned near its $151.97 ATH, ~+60% YTD, but the sell-side has split at the highs: BTIG chased to a $186 PT (2026-07-10) while HSBC cut to Reduce (2026-06-30), the first outright downgrade. Theme SATURATED, no…

Alternatives-manager re-rating: infrastructure and private-credit fundraising (AI-power capex driven) plus a $9.8B contracted-not-yet-fee-paying AUM backlog point to fee-earnings acceleration but reported Q1 FRE was flat YoY and shares sit…

Legacy consumer-security roll-up repaired from $23.31 (2026-06-25) to ~$26, reclaiming the $24 shelf but not the $27.76 earnings high; fresh AI-trust-layer angle (Norton Genie into Claude, 2026-06-30) is real but unmonetized. The…

Sports-data toll-booth under the prediction-market boom, but the boom arrived and the toll didn't: Kalshi/Polymarket cleared $50B+ of World Cup volume (Coindesk, 2026-07-14) while GENI slid $6.43 → $6.30 and printed $5.98 intraday July 17.…

Turbo cash-cow re-rated (~8–9x → ~18x) on a datacenter/industrial oil-free cooling narrative; the parabolic Feb→June leg (~$20→$36) is spent, shares faded ~11% to the 50-day near $32.30, and the ~late-July Q2 print is the first chance to…

BTC-miner→AI-compute re-rating has its first blue-chip proof BUZZ HPC's $220M Bell/Cohere sovereign-AI GPU deal (~$70M ARR) on top of $35M contracted ARR but the stock stalled ~$3.79 — below its early-June highs as BTC bled ~45-50% off…

West Coast office/studio REIT that nearly tripled off the April $5.51 low; operating recovery is real but the move has matured into a split $12–$16 analyst cluster with B of A now at Underperform. The trade is now a binary ~$566M CMBS…

Data-center electrical "shovels" fundamentals still accelerating (Q2 FY26 backlog +62% to $3.9B, Communications +35%), but the June index-inclusion parabola to a ~$800 ATH expired July 1 and a 2026-07-02 shelf prospectus on a…

AI training-data pure-play with a still-accelerating fundamental story (Q1 rev +54%, 40%+ FY26 guide reaffirmed 06-17) but a fully broken chart: ~-51% from the June $125.14 ATH to ~$61, with the CEO filing a fresh 200k-share sale on 07-16…

Former Bitfarms miner→AI/HPC-datacenter pivot has rolled over: June's push to ~$6.14 into Citizens' $10 initiation retraced to a ~$4.975 ref by 07-06, losing the $5.00 convert shelf and drifting toward the $4.00–4.20 base. Still zero…

Cyclical staffing recovery is fully printed Q1 returned to YoY growth, Q2 guided +~4% but price ran ~24% in three weeks to a fresh all-time high near $58.6, ~38% above the $42.33 consensus PT, into the confirmed 2026-07-27 Q2 print. A…

AI-datacenter MEP/HVAC pick-and-shovel story still improving on fundamentals (record $5.38B backlog, FY guide raised to $4.1–4.3B), but the tape has decoupled: ~33% off the $102 May close high, LGN sliced the $76 breakout shelf and rolled…

Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already…

AI/HPC power-buildout re-rate is the leg being bought the 2026-07-09 HIF deal adds up to 2 GW in Texas, lifting potential capacity toward ~4.8 GW but the golden-cross base fully round-tripped to ~$11.4 as analysts cut across the board (MS…

AI-data-center re-rating leg is unwinding round-tripped from the $105.91 May ATH to the ~$84 50-day EMA under an unrebutted J Capital short thesis and a 2026-07-13 TD Cowen PT cut to $90; only the cyclical MCU/industrial recovery (~93% of…

Atlas re-acceleration (+29.4% YoY, record $117M seq add; Q1 FY27, 2026-05-28) is intact, but the +18.5% post-print breakout fully round-tripped from $444.72 to a $294.10 close as the AI-software theme sold on margin-timing fear. Sell-side…

Contracted AI-cooling supplier story is intact $4B+ Airedale capacity agreement through 2029, $165M customer prepayment but the tape has unwound ~29% from the $323.25 May high to ~$229, lost the $260 base, and is -19.4% in a month. The…

AI data-center power narrative still accelerating fundamentally (Enterprise Data ~2x YoY to $262.8M Q1; Q2 guide $890–910M, +35% YoY), but the tape bounced ~12% off the ~$1,200 shelf to ~$1,468 and now stalls at the 50-day into a binary…

AI-capex derating still in control: MSFT closed $393.82 on 2026-07-17, below the ~$414 200-day and the lost $400 shelf, -20%+ YTD, with six brokers cutting targets in one week into the print. The narrative has flipped from "spend to win"…

AI optical-interconnect arms-dealer with fundamentals still accelerating (FY26 DC growth guide >60%, Q3 guide $331-339M) but a July-broken chart: ~36% off the $418.90 high to ~$267 on the semi selloff, Russell Value index removal, and…

AI optical/interconnect re-rating is intact PTs $105–125 (Stifel/Northland/Benchmark, 2026-06-25) versus a stock that ran ~$70→~$96.60 into late June but the name now sits ~5 days from a binary Q2 FY26 print (~2026-07-23), retail coverage…

Legacy plastics maker re-rated ~2.4x on a "Focused Transformation" MTS distribution arm in discontinued ops, capital concentrated behind Signature/MegaDeck composite matting (Infrastructure orders +130% YoY, Q1 adj EPS $0.44 vs $0.28).…

AI-networking legacy re-rate extending on a harder catalyst leg first commercial AI-RAN platform with Nvidia (07-15) plus Taiwan Mobile, Orange Belgium and NestAI defense wins. Theme ACCELERATING, but the 2026-07-23 pre-open Q2 print is a…

AI-native private-flood MGA disrupting the federal NFIP; a rare profitable insurtech (57% adj-EBITDA margin) but revenue growth is decelerating 34%→29% and the sell-side is already fully engaged, with consensus PT $31.23 sitting at/below…

Legacy steel-pipe maker re-rated into a water-infrastructure + precast roll-up on a record $373M WTS backlog, an ~83% Q1 beat, and the Permalok RBJ field win. Narrative intact but the setup is extended last near $148, ~35% above the ~$109…

Freight-cycle recovery led by the top-margin LTL name is now drawing its first upgrades into strength (Evercore to Outperform $237, Jul 1; Goldman Buy $235, Jun 23), but growth is still fuel+price with tons/day -3.8%, targets sit at spot…

Squeeze leg broke: +43% in four sessions to a $63.79 high, then management priced 3.62M shares at $55.22 (~8% discount) and closed ~$191.9M net on 2026-07-06. Price round-tripped to $37.04, under the 20- and 50-day and under the $49…

Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS…

Recovery leg re-fired: $66.06 (2026-06-05) → $71.49 on 2026-07-15 (+5.9%) → $73.20, back within 3% of the $75.25 high and ~6% ABOVE the $68.80 consensus target. Wells Fargo's 2026-07-10 note flags June financing data accelerating into a Q2…

Grid/AI-power second-order narrative has gone mainstream Cramer spotlighted PLPC on 2026-07-15 and the stock is ~5% lower two sessions later at $327.43, now -21% from the $414.35 ATH. Failed breakout plus Russell Value deletion plus a…

The +475% hydrogen-comeback squeeze has broken: the $3.12 Q1 gap and the 50-day both failed, price is ~$2.17 (-20% in 30d), and Susquehanna cut its target $3.75 → $2.50 on 2026-07-10. The June 30 NY Gateway close resolved as a restructure…

The 800VDC AI-power re-rate has cracked. POWI lost the $74–78 May breakout shelf in a -20% week to $70.45 (2026-07-17) and now sits below the $76.20 average target for the first time since spring. The GaN cohort broke with it NVTS is -41%…

Rig-reactivation cyclical is basing, not broken: June averaged 95 US rigs (vs ~90 Q2 guide), the July EIA STEO lifted 2026 Henry Hub to $3.67, gas rigs turned up 122→126, and Piper upgraded to Overweight 07-14. Price bottomed $8.57 (07-01)…

The sell-the-news break is now confirmed: RUM lost the $6.46–$6.66 100/200-day shelf and closed $5.76 on 2026-07-17, -19% from the post-rebrand tape and within 25% of the $4.62 52-week low. Every moving average is overhead. The 2026-08-10…

Agentic-identity story intact and the post-earnings flush is basing: SAIL clawed from a $13.33 low (6/22) back to $15.68 (7/17), a higher low off the $10.30 bottom. Growth decelerated (ARR +26% vs +30%) and guidance was only affirmed, so…

Legacy-EMS AI re-rate (AMD/ZT Systems datacenter manufacturing) blew off to a $282.72 ATH then corrected ~16% off the highs; the est. ~2026-07-27 FQ3 print is now ~9 days out and is the binary it tests whether FQ2's +102% YoY surge was H2…

Online-styling turnaround printed a 5th straight quarter of growth and first sequential client gain (Q3, 2026-06-10), but the stock round-tripped the post-earnings pop back to ~$3.85 amid insider selling and a fresh Mizuho Underperform ($3…

MEMS-timing picks-and-shovels story is fundamentally intact Q1 datacenter revenue +158% YoY to 67% of sales, Renesas timing deal closed July 1 but the momentum leg has broken: ~$550 on July 18 is ~39% off the May 11 all-time-high close of…

Korea AI-infra narrative is loud while the ADR bleeds: $46.00 (06-02) to $30.62 (07-17), and both the 15GW plan (07-05) and JPMorgan's Overweight upgrade (~07-16) failed to hold a bid. The story flipped from AIDC margin accretion to ₩140T…

Dilution leg has broken the story: the $7B raise cleared at $27.50 on June 11 and spot is $24.18, with a live $2B ATM as forward supply. DDR contract prices +32% QoQ crush a business guiding 8.2–8.4% gross margin. Falling knife under all…

AI-interconnect fundamentals still accelerating (Q1 FY27 data center +85% YoY, Needham reiterated Buy/$200 on 2026-07-13), but the price leg has broken: -22.7% in a month to ~$125, through the 20- and 50-day, ~30% off the $177.35 high.…

Legacy web-analytics SaaS (IPO $22, now ~$7) repositioning as an LLM-data supplier: a seven-digit AI training-data contract (disclosed 2026-05-18) plus AI Agents launch is the re-rating story. But Q1 2026 growth decelerated to +10% YoY and…

plus an active SDNY fraud class action keeps the stock below all MAs, churning $13–16. The ~Aug 4 Q2 print, first since the short reports and first with Kalshi, is the binary that decides which narrative wins.

The June AI-data-center re-rating has failed its retest: $62.06 on 2026-07-17 is -22% from the 2026-06-22 high of $79.82 and back under the early-June breakout base, with a $1.5B convertible overhang and a 7% selloff that ignored a BofA…

Picks-and-shovels contractor for the AI data-center buildout; fundamentals still fire (Q1 rev +92% to $825.7M, FY26 EPS guide $16.50–17.15, $6.5B backlog) but the June-4 blowoff has de-rated ~36% to ~$635 in a sector-wide E&C selloff. The…

The AI-datacenter-landlord re-rate has stalled: TH peaked at $20.85 and has given back ~21% to $16.36 (2026-07-17) as TDR Capital affiliates distribute shares in-kind to partners, losing the $17 secondary clearing shelf while Oppenheimer…

Momentum leg snapped: after a fresh ATH ~$223.83, TTMI unwound ~30% in days (-13.2% on 2026-07-02 to ~$156) on a valuation reset, insider distribution and post-Russell-1000 rebalance flow no company news, and no catalyst until the…

Capex-heavy self-storage buildout bolted onto a moving business throttled by multi-decade-low housing turnover; lease-up drags margins while national storage street rates soften. No accelerating narrative and a rangebound tape dead money…

Hyperscaler dark-fiber demand turned the post-Windstream deleveraging grind into a growth story (~$1.5B disclosed funnel, $68.7M of Q1 IRU revenue from one hyperscaler), but the June re-rate to ~$11 has stalled in a three-week range above…

Operating numbers still inflecting (Q2 guide ~$142M, book-to-bill >2.0, backlog $300.6M) but the chart has broken: $237.62 on 2026-07-17 is ~38% off the $382.65 July high, with $271 and $300 both lost and relentless CEO 10b5-1 supply. The…

The precision-components AI re-rate topped at $151.78 and has round-tripped ~32% to $103.89 (2026-07-17), now below the $116.05 50-DMA after a 2026-07-13 gap-down. The narrative leg is unwinding into the 2026-08-05 Q2 print a broken…

H2-2026 leasing inflection plus a data-center vertical guided +50% revenue, under an activist/PE takeover floor but a 2026-06-27 Russell growth-index removal forced passive selling, consensus PTs ($24.25) sit below the ~$27 tape, and the…

Roll-up thesis has broken. Both acquisitions closed on schedule (ALL.SPACE 2026-07-08, $300M; Solestial ~$67M) yet YSS closed $17.93 on 2026-07-17 ~45% below the January IPO range and 4.6% off the $16.93 52-week low. Wolfpack's claim that…

Narrative-momentum thesis is closed: Rocket Lab agreed 2026-06-29 to acquire Iridium for ~$54/share ($27 cash + a calculated ratio of RKLB stock), EV ~$8B. IRDM now trades as merger-arb spread to ~$54 plus embedded RKLB beta not on NTN…

Nasdaq-100 inclusion flow catalyst fired and faded into a sell-the-news; SPCX is now an unbased $1.77T post-IPO decliner (a post-IPO buyer down ~23%) in the Figma/Circle retreat cohort, with lock-ups ahead and China closing the…

Conway extract/RTD platform inflecting capex to cash: Q1 (5/07) beat revenue with record adjusted EBITDA, FCF-positive-H2 guide reaffirmed, and a 6/30 debt-maturity extension cleared the near-term refi wall. Stock re-rated ~the published…

Life-settlements franchise attached itself to the RWA-tokenization narrative on 2026-07-07 (100+ policies on-chain, targeting the $224B secondary market by year-end); Q1 beat and raised FY adj-EPS guide to $1.00–1.05. But price rejected…

Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares…

AstroNova is a closed narrative: Arcline's $29.00 all-cash take-private (announced 2026-06-17, ~$272M, Q3-2026 close) hard-caps the stock. The 200%+ pop was a one-time buyout gap, not an accelerating story what remains is a thin merger-arb…

Pure-play Jemperli/imsidolimab royalty stub since the April spin-off; the entire equity now hinges on the 2026-07-14–17 Delaware Chancery trial on royalty reversion and rate preservation now 1–3 trading days out. A binary legal verdict,…

Precision-psychiatry re-rate that has already run ~10x off a $2.50 low to near its $28.44 high; funded through 2029 on the March $120M PIPE, but every binary readout (ALTO-300, ALTO-100, ALTO-207 in TRD) sits in 2027 the tape near highs is…

Gold/copper producer basing $53–$76 — below its broken ~$72 shelf after a ~45% drop from the $110 high. Q2 production slipped 8% QoQ (first sequential decline after a record Q1) as gold stalls in the low-$4,000s and sell-side trims targets…

All-cash $25.00 take-private of Avanos by American Industrial Partners is now a near-closed pin: all regulatory approvals obtained 2026-07-02, leaving only the 2026-07-22 shareholder vote before an expected close by 2026-07-27. The spread…

Value-unlock special situation, not momentum: ~$10.90/share net cash, Politan (~10%) on the board, and portfolio simplification now executing B Medical Systems divestiture closed Jul 8. But the +60% bounce off $15.93 has stalled in the…

Distress jumped from the Idesa JV to the parent: ~2026-06-29 Braskem S.A. won a 60-day creditor standstill, Fitch cut to C and S&P to D (default), and JPMorgan capitulated to Neutral (2026-06-30) as creditors rejected management's plan and…

The premium-to-book re-rating has unwound: BH ~$384 (Jul 17) sits back under the ~$401/Class B book line while CBRL rallied to $53.61 the holdco is falling as its main asset rises, re-widening the discount. A $500M ATM with ~$485M undrawn…

Broken IPO (~$5.13 vs $18 Jan listing) that just printed a fresh all-time low at $4.67 as the 2026-06-17 buyback bounce faded rolling into a 2026-07-21 lockup unlock (~10 days out), a new 15% layoff, and a fresh IPO-period securities class…

Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,…

CAN-2409 narrative re-armed on the 2026-06-30 AURORA Phase 3 launch in post-ICI NSCLC a second pivotal program in a far larger indication plus an ex-AstraZeneca lung CCO hire; the stock cleared the old $9.27 high to an $11.36 peak, then…

Deal-pinned cash merger-arb, not a momentum trade. Knox Lane taking CCRN private at $13.25 cash; HSR cleared 2026-06-22 for both the merger and the locums sale, leaving only the 2026-07-16 shareholder vote. ~0.3% capped upside vs ~25%…

Humanoid-robotics de-SPAC: Churchill XI merges with Agility Robotics (~$2.5B, Nvidia/Amazon-backed, re-lists as AGLT). Theme intact, but the tape is an RSI-98 filing-driven blow-off that has since gone quiet with no dated catalyst until…

Resolved special situation: Lilly closed its $38.00 cash plus up-to-$9.00 non-transferable CVR scheme on 2026-06-24 after the 2026-06-22 High Court sanction; last Nasdaq ADS trade was 2026-06-23 and shares have delisted and are…

Post-fraud recovery (+~115% off the $4.58 low) has stalled: a 2026-07-01 +9% pop to $11.57 faded back under the 50-day (~$11.14) to ~$10.08 by 2026-07-08 on volume 53% below average. Only live optionality is the delayed Management Services…

Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical…

Deal-or-no-deal special situation: the 2026-07-06 Vista/Quinti take-private bid >$50 against a ~$23 tape implies the market prices only low-teens completion odds, earned by Criteo's serial failed-sale history. The momentum pop already…

Currency/payments spinoff re-rating into an authentication & traceability roll-up (De La Rue + Antares Vision); SAT sales +51% YoY, FY sales guide hiked to 15–17%. A June 27 Russell large-cap ejection forced a washout to ~$47.48; price is…

Deleveraging-and-refranchising turnaround with a now-dated catalyst: Q2 FY2026 prints 2026-08-06. Net leverage cut to ~5.5x from 6.7x, liquidity >$300M, but revenue still shrinks and ~23-29% of the float is short. The tradeable energy is a…

Closed-end SpaceX proxy whose entire bull case the pre-IPO scarcity premium is now dead: SpaceX trades publicly (SPCX, $135 IPO 2026-06-12, ran to $225, back near ~$145 lows by 2026-07-10). DXYZ's premium has collapsed from ~151% (May)…

WFE-upcycle consumables re-rate now MATURING: after a +30% two-week run to ~$181 on the JSR/Inpria EUV cross-license and CNBC coverage, July sell-side is splitting Mizuho to $200 (07-01) vs Deutsche Bank Hold $155 (07-06), BMO $167 with…

ARCHIMED take-private cleared its last binary: the 2026-07-08 vote adopted the deal (135.3M for vs 22.8M against), and with HSR and German antitrust already done only the mechanical Q3 close and Nasdaq delisting remain. Stock is pinned at…

Matured auto/home insurance lead-gen cyclical that re-rated on the tape: a +6.91% breakout on 2026-06-26 (~4x average volume) reclaimed the declined ~$20.30 200-DMA, confirmed by a live estimate-revision cycle (Zacks consensus EPS +21% in…

Activist-plus-new-CEO turnaround has stopped accelerating and started digesting: after the +30% run off Garden's $40.6 buy, price has chopped $50–54 for three weeks while sell-side targets climbed past spot (Goldman $61 on 7/10, Barclays…

CRO margin-turnaround already re-rated FTRE ~4x off its 2025 low; the Q1 beat that drove it is spent and price sits ~9% under the $18.67 52-week high, above most analyst targets. Fresh positive drift (Zacks Strong-Buy 7/7 on +31% estimate…

Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited…

Signed $9.50/share cash take-private by Long Lake (~$6.3B; General Catalyst + Alpha Wave backed); 69% of shares locked via voting agreements, close guided 2H 2026. Stock pinned ~$9.36 pure merger-arb with ~1.5% capped upside vs ~37%…

Alternatives-manager re-rating: infrastructure and private-credit fundraising (AI-power capex driven) plus a $9.8B contracted-not-yet-fee-paying AUM backlog point to fee-earnings acceleration but reported Q1 FRE was flat YoY and shares sit…

The operating turnaround is real but priced, and its one asymmetric leg the activist proxy fight lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the…

Turbo cash-cow re-rated (~8–9x → ~18x) on a datacenter/industrial oil-free cooling narrative; the parabolic Feb→June leg (~$20→$36) is spent, shares faded ~11% to the 50-day near $32.30, and the ~late-July Q2 print is the first chance to…

Q1 FY2027 (2026-07-08) beat the guided-breakeven bar Adj EPS $0.17 vs $(0.01) est, sales $402M vs $375M, sales guide nudged up and analysts lifted PTs to $25–28. The turnaround binary resolved favorably, but the stock now sits at fair…

West Coast office/studio REIT that nearly tripled off the April $5.51 low; operating recovery is real but the move has matured into a split $12–$16 analyst cluster with B of A now at Underperform. The trade is now a binary ~$566M CMBS…

Precision-oncology name digesting a $300M raise at $27.00 (priced 2026-06-09); analysts cut targets 2026-07-07 (RBC $48, Truist $63) while staying bullish. Darovasertib uveal-melanoma registrational path is the embedded option, but the…

M&A special-sit stays the dormant leg SiriusXM talks stalled over the divestiture/antitrust impasse and unrevived but the $6.56 April spike stabilized near $4.05 instead of bleeding out, and a fundamental H2 story (2026 midterm…

Post-ASCO sell-the-news biotech: atebimetinib's 17.3-month first-line pancreatic OS is real but single-arm, and the Phase 3 OS binary is ~2 years out (mid-2028). Near-term is a coverage and base-building story with no dated OS catalyst…

Halted micro-cap: the $39.49 last print (June 8, 2026) was a 3,660% blow-off from $1.05 on a $3M AI 'used-phone sales agent' deal, after which Nasdaq froze it under T12 and the board opened a probe into its own trading. No live tradeable…

Up ~39% YTD on a rotation-into-quality-defensives bid, but FY2026 guidance is EPS $4.85 a ~5% decline as Interparfums invests through a trough year toward a 2027 license rollout. The move is multiple expansion, not earnings; sell-side PTs…

Special-situation biotech, not momentum: the 2026 Linzess pricing-restructure re-rate faded to the low-$3s, then bounced ~30% to a $4.65 close July 8 on M&A speculation with no confirmed bid, since fading to ~$4.21. The Aug 6 Q2 print is…

June's move was a float mechanic Russell Microcap inclusion (effective 2026-06-30) into a 40%-short float drove $8.92 to $18.13, and it is unwinding ($14.98 on 2026-07-17, -7.76%). SSS is genuinely inflecting (-6.7% → -3.8%), but price…

Closed takeout, not a security: Chiesi's $27.00/share all-cash acquisition of KalVista completed 2026-06-11, shares delisted from Nasdaq with deregistration (POS AM, Form 25, Form 15) underway. No spread, no momentum leg, no listed share…

Pension-reversion fat pitch fired and is spent; the re-rate has fully unwound from the $14.87 May high to ~$7.78, losing the $9 June shelf and printing a $4.94 52-week low. A July 1 resale shelf of up to ~39.46M shares and a June 29 Sell…

Ziftomenib/Komzifti approval (2025-11-13) already de-risked the story; the Street's $24-28 targets underwrite a frontline-AML expansion gated to a 2028 Phase 3. Stock consolidates near its $12.49 52-week high on a slow launch ($5.8M Q1)…

The 2026 lithium-recovery narrative has broken: CATL's ~46ktpa Jianxiawo mine restarted 2026-06-29, pulling the supply-discipline leg out from under the rally. China carbonate fell to a ~4-month-low CNY 151,000/t and LAR sliced its $7…

Contested insurtech IPO reclaimed its $19 price in a late-June ~28% rip and has held it into a fresh JPM Overweight (PT $23, 2026-07-13). But the reclaim runs into the 2026-07-27 final lock-up and an unresolved upfront-accounting short…

Insider-cluster leg has already paid: Malone/Fries/Nair bought the post-distribution $4.98 June base, and the common is $7.34 ~47% higher in under a month. July brought Citi's downgrade to Neutral (PT $8) and a Barclays Underweight at…

Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already…

Q1 FY27 (2026-06-11) beat in a shrinking furniture category, but the tape refused the news and no volume-confirmed reclaim has fired five weeks on. With ~27–31% short float and clustered June insider buys, the only live edge is a squeeze…

Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low so the trade is now a bump handicap, not a growth story. At ~$46.91…

Re-rating leg has stalled: NUTX closed $162.98 on 2026-07-17 after five straight down days, ~20% off the $204.00 high, giving back the June breakout that B. Riley's 2026-06-26 Buy/$290 initiation topped out. A $55.0M true-up of 18,950…

Takeover binary is resolved and deal-pinned: OGN trades ~$13.51 into Sun Pharma's $14.00 all-cash offer, a ~$0.49 (3.7%) gross spread. The 2026-07-06 disclosure suit was mooted by 2026-07-17 supplemental proxy filings, clearing the path to…

Closed by event: the Henkel all-cash takeout completed and OLPX was delisted from Nasdaq on 2026-07-07, with each share converted into the right to receive $2.06 cash. There is no longer a listed security, no price series, and no thesis to…

PBI broke the $17.62 shelf to a fresh 52-week high $18.62 (Jul 16) the buyback/cost-cut re-rate is now extending, not consolidating. But revenue still shrinks ~3% YoY, consensus PT $16.43 sits below spot, and Q2 prints after close Jul 29.…

Recovery leg re-fired: $66.06 (2026-06-05) → $71.49 on 2026-07-15 (+5.9%) → $73.20, back within 3% of the $75.25 high and ~6% ABOVE the $68.80 consensus target. Wells Fargo's 2026-07-10 note flags June financing data accelerating into a Q2…

Special-situation setup: an April-2026 strategic review (Morgan Stanley engaged) puts a possible sale on a controlled, down-~90%-from-IPO name, while record DTC revenue (+62.8% YoY) and Disney Solitaire drove a Q1 guidance raise. The Aug 6…

Deal-rumor re-rate has already run: $13.79 (Jun 26) to $17.38 (Jul 17), +75% off the $9.92 low, on an unsigned ~$1.5B point-of-care divestiture. Sell-side chased it up (Citi $13→$18). The Aug 4 Q2 print is the binary, and a shrinking base…

Merger spread, not a story: SWKS collapsed ~25% on Apple iPhone content loss, dragging implied deal value ($32.50 + 0.960 SWKS) from ~$102 to ~$87.7 while QRVO sits $85.50 under 3% left for underwriting a China SAMR Phase II review with no…

Merger-arb stub, not a momentum vehicle: the Publicis $38.50 all-cash deal now has a dated shareholder vote (2026-08-17, 66⅔% threshold) and HSR filed 2026-06-11. At ~$37.82 the remaining spread is ~1.8% into a year-end close, against…

MEMS-timing picks-and-shovels story is fundamentally intact Q1 datacenter revenue +158% YoY to 67% of sales, Renesas timing deal closed July 1 but the momentum leg has broken: ~$550 on July 18 is ~39% off the May 11 all-time-high close of…

China EVO+ recovery leg is decelerating: Q2 prelim (2026-07-16) of ">$90M" was in-line, sequentially below Q1's $93.52M, and drew an 8.8% gap-down that broke the $29.43 50-day. Triple-digit YoY comps end here, the M&A binary died at the…

All-stock takeout capped the story and the acquirer de-rated: ON's ~19% announcement drop and slide to $87.37 cut the 1.350-ratio implied value from ~$160 to ~$118, with SYNA at $114.05. What's left is a 3.4% gross spread to a mid-2027…

Terminated, not traded: the IKS Health merger closed 2026-07-09 at $26.25/share cash after the 2026-07-07 vote passed 11.31M for / 8,818 against. Shares were cashed out and delisted from Nasdaq. No tradable equity remains; the ticker is a…

Closed merger-arb: shares pinned just under Merck KGaA's $73 all-cash bid (06-25, $11.3B EV, expected close late-2026/early-2027). The full sell-side has folded targets to $73 (RBC 07-09 the latest). No narrative leg left only thin spread…

Panagiotidis shipping shell (NOT lawnmower TTC) ran 1.93→8.50 on a sub-NAV/special-dividend story that is now fully paid out and closed. Six weeks of dead tape since the 2026-06-05 payout ($3.8M cash + 5,707,246 NEW shares); on a true…

Hyperscaler dark-fiber demand turned the post-Windstream deleveraging grind into a growth story (~$1.5B disclosed funnel, $68.7M of Q1 IRU revenue from one hyperscaler), but the June re-rate to ~$11 has stalled in a three-week range above…

Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes passed 2026-02-06, only China SAMR remains (outside date 2026-09-30). Upside is ratio-capped and the live binary is the SAMR sign-off which has run slow and may move…

H2-2026 leasing inflection plus a data-center vertical guided +50% revenue, under an activist/PE takeover floor but a 2026-06-27 Russell growth-index removal forced passive selling, consensus PTs ($24.25) sit below the ~$27 tape, and the…

Activist-anchored distressed-deleveraging special situation that fully round-tripped the June pop: $3.49 (2026-06-04) back to ~$2.80 (2026-07-02, -9.7% on the day), now at/below the $2.50 average target after Citi cut $3.50→$2.50.…

Delisting binary resolved to the survive side: EGM passed 2026-06-29, Psyga psilocybin reverse-merger closed 2026-06-30, delinquent 20-F filed, Nasdaq listing held. ADS popped ~+90% intraday to ~$2.70 (~$6.4M cap). Now an illiquid…

The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the…

Conway extract/RTD platform inflecting capex to cash: Q1 (5/07) beat revenue with record adjusted EBITDA, FCF-positive-H2 guide reaffirmed, and a 6/30 debt-maturity extension cleared the near-term refi wall. Stock re-rated ~the published…

Lemonis "Everything Home" roll-up accelerating on deal cadence (TwoPonds, Affirm BNPL, Tokens.com, all ~2026-07-01), but the BBBY tape stays pinned near its 52-week low (~$5.83 vs $4.26) a story-stock value trap until price reclaims…

Rotation-passenger thesis is dead: BBWI broke its multi-year base and sits ~36% off its high near 52-week lows while the tape makes records. Only live leg is a nascent self-help turnaround Ulta wholesale launch 2026-07-12, Consumer First…

Tape flipped since early July: BBY broke to a fresh 52-week high $87.35 (~$85.41 on 2026-07-17, +27.6% YTD) on RGB-LED TV exclusivity plus an AI-PC/MacBook refresh cycle. But price sits ~8% above the $79.15 consensus target while Loop…

The premium-to-book re-rating has unwound: BH ~$384 (Jul 17) sits back under the ~$401/Class B book line while CBRL rallied to $53.61 the holdco is falling as its main asset rises, re-widening the discount. A $500M ATM with ~$485M undrawn…

Post-miss +46% V-recovery has rolled over ~$44 from a ~$48.75 June high, never retesting the $53.53 ATH. The tell: fresh $500M buyback authority funded by the June 19 €900M notes landed and the stock still faded. S&P cut the outlook to…

Casual-dining turnaround already re-rated: seven straight quarters of traffic growth under CEO Tick, but Q1 comps decelerated to +2.4%, FY guide is just +1–3%, price sits ~30% above every analyst PT, and insiders sold the June high. Mature…

Broken protein-staple turnaround; the June–July bounce off the $7.82 low is oversold mean-reversion, not re-acceleration. A new CEO effective July 29 and Stephens' $20 PT are scaffolding the ~Aug 3 Q3 print is the binary that validates or…

Drive-thru coffee comps re-accelerating (Q1 +8.3%, FY guide raised) and the sell-side is now catching up Stephens initiated Overweight $80, Morgan Stanley to $88 in mid-July. But June's run to ~$72 cooled to the mid-$60s, and the…

Casual-dining re-rate got a genuine second leg: Citi's 2026-07-10 raise to a street-high $90 (Buy) on a rewards/app traffic-inflection thesis gapped shares 7% to all-time highs (~$86, 52wk high $86.66 on 2026-07-18). For the first time the…

Post-earnings drift has cut the stock ~19% from its pre-print ~$14.51 to $11.81 (2026-07-10), slicing the low-$13s June base as the spent Q1 catalyst left no momentum leg. Cheap on forward numbers (~7.7x, ~$57.8M tariff-refund optionality…

Capital-light auto marketplace compounding per-share via a 29%-of-float buyback and steady ~15% marketplace growth, but the theme is MATURING, growth is decelerating (Q2 guide +11-14% vs Q1 +15%), and the 2026-08-06 print is a binary with…

Q3 FY26 beat + raised FY26 guide ($3.27–3.30B vs $3.25B) confirmed the legacy-diner turnaround, but the catalyst fired five weeks ago, the rotation cooled to maturing, and the next print is ~September. A 2026-07-13 13G/A (D.E. Shaw…

Sell-side cluster finally formed Citi Buy/$45 and Mizuho Outperform raised to $41 (both 2026-07-13) joining JPM's Overweight, plus first Mexico restaurant announced but the ~2026-07-22 Q2 print is three days out and no weekly 20-EMA…

Coconut-water category leader re-rated ~+130% off the $31.79 low on a real Q1 FY26 blowout, but that catalyst is now ~10 weeks stale and the swing-momentum signal round-tripped (bought 6/3, sold 6/18). The 2026-07-09 Piper PT raise landed…

Citi Trends' value-apparel turnaround is real and accelerating Q1 FY2026 comps +13.9%, a 21-month positive streak, and a raised full-year guide but the 2026-06-02 print was the catalyst and it fired five weeks ago. On an ~8.1M-share float…

Deleveraging-and-refranchising turnaround with a now-dated catalyst: Q2 FY2026 prints 2026-08-06. Net leverage cut to ~5.5x from 6.7x, liquidity >$300M, but revenue still shrinks and ~23-29% of the float is short. The tradeable energy is a…

A rejected $30/share Yellow Wood bid (2026-06-22) flips EPC from dead-tape value-trap to a live take-private special situation the board refused outright as too low and shares gapped +18% to new highs near $27. The leg being bought is M&A…

Activist-plus-new-CEO turnaround has stopped accelerating and started digesting: after the +30% run off Garden's $40.6 buy, price has chopped $50–54 for three weeks while sell-side targets climbed past spot (Goldman $61 on 7/10, Barclays…

Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary…

Signed $9.50/share cash take-private by Long Lake (~$6.3B; General Catalyst + Alpha Wave backed); 69% of shares locked via voting agreements, close guided 2H 2026. Stock pinned ~$9.36 pure merger-arb with ~1.5% capped upside vs ~37%…

The operating turnaround is real but priced, and its one asymmetric leg the activist proxy fight lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the…

Premium-golf consumable franchise (Titleist Pro V1) catching a defensive-quality rotation bid; JPM's 2026-06-26 Positive Catalyst Watch (PT $96→$118, Q2 growth 11.8% vs 10.3% cons) frames the ~2026-08-06 Q2 print as the confirmation. But…

Q1 FY2027 (2026-07-08) beat the guided-breakeven bar Adj EPS $0.17 vs $(0.01) est, sales $402M vs $375M, sales guide nudged up and analysts lifted PTs to $25–28. The turnaround binary resolved favorably, but the stock now sits at fair…

Transformational Steelcase merger (closed 2025-12-10) made HNI the #1 North American office-furniture maker at ~$5.8B revenue, but the tape is broken near $40 versus ~$70 analyst targets a show-me integration grind, not an accelerating…

Up ~39% YTD on a rotation-into-quality-defensives bid, but FY2026 guidance is EPS $4.85 a ~5% decline as Interparfums invests through a trough year toward a 2027 license rollout. The move is multiple expansion, not earnings; sell-side PTs…

June's move was a float mechanic Russell Microcap inclusion (effective 2026-06-30) into a 40%-short float drove $8.92 to $18.13, and it is unwinding ($14.98 on 2026-07-17, -7.76%). SSS is genuinely inflecting (-6.7% → -3.8%), but price…

Genuine FY2026 turnaround (loss→$3.6M net, record $166M rev) plus a +20–22% Q1 guide drove a +36% circuit-breaker gap on 2026-06-15. Three weeks on the catalyst is spent, no fresh news since June 18, RSI-88.6 momentum has bled off the gap…

Squeeze leg has stalled: Morgan Stanley's 2026-07-06 Underweight/$15 reinit broke the one-way upgrade cluster and knocked the stock -5.9% on 07-08. Price ~$17.18 still holds above the 50- and 200-day, but with the sell-side now two-sided…

Q1 FY27 (2026-06-11) beat in a shrinking furniture category, but the tape refused the news and no volume-confirmed reclaim has fired five weeks on. With ~27–31% short float and clustered June insider buys, the only live edge is a squeeze…

Morgan Stanley broke the all-Hold wall on 2026-07-06, resuming at Overweight with a $30 target and a $3 EPS-power call vs ~$2 consensus the first real upgrade catalyst since the Q1 beat. But price faded the note ($23.99 → $22.64 by 07-12)…

Deli prepared-foods roll-up keeps compounding Q1 FY2027 (2026-06-08) revenue +49.7% YoY but management top-ticked the 52-week high with a $100M raise at $18.00 (2026-06-30): ~14% dilution, momentum reset, theme cooling to maturing. No…

Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low so the trade is now a bump handicap, not a growth story. At ~$46.91…

Cheap cyclical furniture name squeezed ~24% off its 2026-06-24 post-earnings $17.29 close to $21.42, pressing the $23.18 52-week high but on a decelerating narrative: Q4 orders -6.3%, backlog -10.8%, a downgrade to Hold, CEO-transition…

India-OTA recovery bounce, not a fresh breakout: MMYT is +79% off the $32.67 low and just reclaimed the 200-day (~$55) after HSBC's 2026-07-02 Buy/$70 initiation but a MATURING travel theme runs straight into a binary Q1 FY2027 print…

Margin-led re-rate (Q1 FY27 GM 57.3%, +320bp; adj EPS $0.32 vs $0.08 est) is already priced at $38.65, ~3% off the $39.85 high after six weeks of chop. The live variable is the 2026-07-24 Section 122 expiry: the 10% Swiss-watch surcharge…

Housing-rebound-on-rate-cuts trade that carried MTH to a $85.38 52-week high has reversed: it lost the $75 June breakout shelf to $74.17 (-4.2% on 7/17) as mortgages held at 6.49% and Zelman capitulated to Neutral (7/7). Fundamentals still…

Cruise complex re-rating on the fuel-cost collapse from the 2026-06-15 U.S.–Iran peace deal; NCLH is the highest-torque, most-levered name. Sell-side has now clustered ($22–25 PTs: Citi, Wells Fargo, TD Cowen), signaling the theme is…

Post-capitulation base attempt, not an accelerating narrative: the 2026-06-30 print cleared a floored bar off the $41.35 low, but 2026-07-01 brought target cuts across eleven-plus desks with the average compressing to the low $50s the same…

Overbought low-dollar turnaround bounce running straight into a binary ~7/31 earnings print. The only bullish flow, a 6/10 sweep of Jul-17 $5 calls, expires two weeks BEFORE the report a short-dated $5-reclaim bet, not an earnings…

Broken DTC-beauty flywheel: IL MAKIAGE's ad-acquisition engine seized on a CPA blowout, Q1 first orders -50%, stock crashed $77→$9.25. The ~$18 bounce sits above nearly every Street PT ($8–$12) into a Q2 print (~mid-Aug) still guided…

Closed by event: the Henkel all-cash takeout completed and OLPX was delisted from Nasdaq on 2026-07-07, with each share converted into the right to receive $2.06 cash. There is no longer a listed security, no price series, and no thesis to…

Recovery leg re-fired: $66.06 (2026-06-05) → $71.49 on 2026-07-15 (+5.9%) → $73.20, back within 3% of the $75.25 high and ~6% ABOVE the $68.80 consensus target. Wells Fargo's 2026-07-10 note flags June financing data accelerating into a Q2…

The 2026-06-15 binary resolved against the bulls comps -5.4%, revenue -1.5% YoY to $559.2M, EPS $0.16 vs ~$0.60 consensus and the short-covering squeeze round-tripped to ~$11.30. No catalyst until the ~September Q2 comp print tests the…

Special-situation setup: an April-2026 strategic review (Morgan Stanley engaged) puts a possible sale on a controlled, down-~90%-from-IPO name, while record DTC revenue (+62.8% YoY) and Disney Solitaire drove a Q1 guidance raise. The Aug 6…

Profitable e-commerce-acceleration hypergrowth (Q1'26 rev +43%, NRR 127%) that went parabolic off the June Russell inclusion; now ~20% above the $22.88 average analyst target and overbought into the 2026-08-05 Q2 print. The narrative…

Post-print wreckage, not a turn. FY26 EPS held only via a ~$100M one-time tariff refund while the revenue guide went flat (2026-06-03, −25% overnight); BofA capitulated to Underperform/$70 on ~50% EMEA exposure (2026-06-25). The bounce to…

Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary it needs a DAU inflection…

Luxury-resale turnaround has reached a real profitability inflection Q1 2026 (reported May 7) GMV +24%, revenue +19%, adjusted EBITDA tripled to $13.1M, FY guide raised. But the re-rate off the $4.91 low is largely spent: range-bound near…

June's +20% deleveraging bounce has fully round-tripped: $1.99 (6/26) back to $1.73 (7/17), now under the 50-day near $1.79 after failing exactly at the $1.99 consensus PT. Balance sheet is fixed, narrative is not accelerating, and a…

Online-styling turnaround printed a 5th straight quarter of growth and first sequential client gain (Q3, 2026-06-10), but the stock round-tripped the post-earnings pop back to ~$3.85 amid insider selling and a fresh Mizuho Underperform ($3…

Cyclospora outbreak crushed SG from ~$9 to $6.15 (Jul 16) on guilt by association; FDA traceback cleared it Jul 17 (source: Taylor Farms iceberg at Taco Bell), sparking an 18% bounce to ~$7.08. Now below the $7.92–$8.43 consensus with…

Tariff-recovery leg has stalled into a $39.71–$47.11 range with insiders selling every rally and zero buys; the whole story now hinges on the confirmed 2026-07-30 Q2 print. Consensus targets sit at or below spot ($43.75, 07-16), adjusted…

AR-pivot flagship the $2,195 SPECS glasses (2026-06-16) was rejected by the tape (−4%, design panned), and sell-side is now cutting targets DOWN through $5–6 (Wells $5, DA Davidson $5, Goldman $6, first week of July) into a hardening…

Busted-IPO thrift retailer grinding a base on consumer trade-down plus a June 2 debt-cost cut; the June 27 Russell index deletion pulled the passive bid and capped the bounce near $10, and no hard catalyst lands until the ~Aug 7 Q2 print.…

Tariff/de-minimis "secondhand wins" narrative that drove a ~$2→$12 run has matured into a show-me story; stock rolled to ~$7 with analyst PTs being cut, and the 2026-08-03 Q2 print is the binary on whether AI-first marketplace and the new…

Capex-heavy self-storage buildout bolted onto a moving business throttled by multi-decade-low housing turnover; lease-up drags margins while national storage street rates soften. No accelerating narrative and a rangebound tape dead money…

Q1 blowoff (+47% on 2026-06-02, adj EPS $0.60 vs $0.32) already re-rated the equity; shares ran to a $88.57 high then faded to the mid-$70s. Activist overhang cleared, sell-side neutralizing, no dated catalyst until the ~Aug-26 Q2 print. A…

Margin-inflection turnaround: Q1 (Apr 30) printed a 5-year-best adjusted EBITDA margin of 5.2% on +7.4% revenue, and Evercore's Jun 23 hike to $100 (+9.1% session) reignited the recovery. At ~$95 the stock is mid-range ~20% under its Jan…

First annual same-store-sales decline in 22 years (Q1 2026 domestic SSS -8.7%) broke the compounder narrative; a ~50% relief bounce off the $116 low now runs into the July 29 Q2 print the binary on the guided H2 return to positive comps.…

Quality home-furnishings compounder riding the consumer-discretionary rotation; Q1 (2026-05-21) reaccelerated every brand to positive comp and the sell-side is catching up (Evercore→$230 6/23, B of A $250 6/12). But near $226 the tape sits…

Delisting binary resolved to the survive side: EGM passed 2026-06-29, Psyga psilocybin reverse-merger closed 2026-06-30, delinquent 20-F filed, Nasdaq listing held. ADS popped ~+90% intraday to ~$2.70 (~$6.4M cap). Now an illiquid…

Tariff-margin-recovery turnaround stalled under the $51.89 multi-year high: China now <5% of 2026 COGS and FY guide raised, but a fresh Canaccord Hold/$45 target (2026-06-23) sits below spot and the whole trade is now a binary on the…

The data-center re-rating already failed: QCOM spiked to a 52-week high of $259.92 on the ~2026-06-24 Investor Day $15B-by-2029 guide, then gave back ~34% in 17 sessions to $171.78 as Hold downgrades and Apple modem-attrition math…

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs SPY003 IL-23 Part A (guided mid-2026, overdue)…

Pure-play Jemperli/imsidolimab royalty stub since the April spin-off; the entire equity now hinges on the 2026-07-14–17 Delaware Chancery trial on royalty reversion and rate preservation now 1–3 trading days out. A binary legal verdict,…

Precision-psychiatry re-rate that has already run ~10x off a $2.50 low to near its $28.44 high; funded through 2029 on the March $120M PIPE, but every binary readout (ALTO-300, ALTO-100, ALTO-207 in TRD) sits in 2027 the tape near highs is…

Between-catalyst psychedelic leader jolted by a 2026-07-06 volume spike on an unconfirmed M&A-blog takeout rumor, stacked on Russell 2000/3000 inclusion (effective 2026-06-29) and a Canaccord PT bump to $17 (2026-07-07). The one hard…

Broken-growth AID-pump name in a pre-earnings holding pattern: the ~2026-07-28 Q2 print is the binary that decides whether new patient starts re-accelerate or post a second straight sequential decline. June's ~$14 relief bounce off the…

Left-for-dead pivot re-rated ~6x off $4: oral NLRP3 inhibitor BGE-102 reframes BIOA as a "statin-for-inflammation" CV play after median 86% hsCRP cuts in Phase 1. QUELL-CV Phase 2 topline (2H 2026) is the binary. Now grinding fresh 52-week…

CAN-2409 narrative re-armed on the 2026-06-30 AURORA Phase 3 launch in post-ICI NSCLC a second pivotal program in a far larger indication plus an ex-AstraZeneca lung CCO hire; the stock cleared the old $9.27 high to an $11.36 peak, then…

Analyst-confirmed profitability inflection (Q1'26: adj-EBITDA +$4.0M, +$6.2M op cash, +24% product rev) in a 25-year blood-safety grinder but the 2.7x off the lows is largely spent and price is pinned at 52-week highs (~$3.19 vs $3.21).…

Resolved special situation: Lilly closed its $38.00 cash plus up-to-$9.00 non-transferable CVR scheme on 2026-06-24 after the 2026-06-22 High Court sanction; last Nasdaq ADS trade was 2026-06-23 and shares have delisted and are…

Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry…

Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical…

CGT cold-chain picks-and-shovels; the 2026 re-rate has matured. Consensus PT drifted to $15.11 (now just below the ~$15.26 spot), the rating softened to Moderate Buy with two holds added, and insiders distributed into the early-June $16.73…

ARCHIMED take-private cleared its last binary: the 2026-07-08 vote adopted the deal (135.3M for vs 22.8M against), and with HSR and German antitrust already done only the mechanical Q3 close and Nasdaq delisting remain. Stock is pinned at…

Q1 beat-and-raise (adj EPS $0.14 vs $0.09, FY26 guide lifted above $120M, 2026-05-14) confirmed the specialty-pharma rollup, but the story stopped accelerating in mid-May and now drifts through an empty window into the ~August Q2 print the…

CRO margin-turnaround already re-rated FTRE ~4x off its 2025 low; the Q1 beat that drove it is spent and price sits ~9% under the $18.67 52-week high, above most analyst targets. Fresh positive drift (Zacks Strong-Buy 7/7 on +31% estimate…

Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No…

Commercial ophthalmology special-situation trading on one number: does the guided H2 ramp print. June–July portfolio launches (VERKAZIA, BYOOVIZ) keep sentiment alive, but the binary is the ~Aug 10 Q2 report $71–81M guide vs $44.2M Q1. A…

Precision-oncology name digesting a $300M raise at $27.00 (priced 2026-06-09); analysts cut targets 2026-07-07 (RBC $48, Truist $63) while staying bullish. Darovasertib uveal-melanoma registrational path is the embedded option, but the…

Near-term regulatory binary resolved favorably FDA accepted the ozekibart chondrosarcoma BLA on 2026-06-15 (PDUFA 2027-04-14) but that docketed the defining decision ~9 months out, dropping the name into an extended catalyst vacuum.…

Special-situation biotech, not momentum: the 2026 Linzess pricing-restructure re-rate faded to the low-$3s, then bounced ~30% to a $4.65 close July 8 on M&A speculation with no confirmed bid, since fading to ~$4.21. The Aug 6 Q2 print is…

Both binaries this stock coiled around have fired and are spent: JADE101's clean Phase 1 (2026-06-01, ~70% IgA reduction, q12w dosing) and Vera's TRUTAKNA accelerated approval (2026-07-07), which validated the APRIL/BAFF mechanism but put…

Closed takeout, not a security: Chiesi's $27.00/share all-cash acquisition of KalVista completed 2026-06-11, shares delisted from Nasdaq with deregistration (POS AM, Form 25, Form 15) underway. No spread, no momentum leg, no listed share…

ABC-platform redemption arc: after the 2022 DAZZLE wet-AMD miss took KOD to $4.60, back-to-back positive Phase 3 diabetic-retinopathy readouts (GLOW1, GLOW2) re-rated it ~9x. The September 2026 DAYBREAK wet-AMD topline is the binary either…

Pension-reversion fat pitch fired and is spent; the re-rate has fully unwound from the $14.87 May high to ~$7.78, losing the $9 June shelf and printing a $4.94 52-week low. A July 1 resale shelf of up to ~39.46M shares and a June 29 Sell…

In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst…

Flu-vaccine approval story confirmed by an early-July sell-side PT cluster-raise (Piper $77, RBC $45, MS $39, BofA $34→$38), but the clean +30% momentum leg already ran into the June 18 9-0 advisory vote. The Aug 5 mRNA-1010 PDUFA is now…

TRIDENT's OS miss (2026-06-18) killed the re-rating leg the 2026 markup was built on; JPM's 2026-07-13 reinstatement at Neutral/$17 confirms sell-side capitulating toward the ~$15-16 tape. A +12% YoY, loss-making single-asset device name…

Takeover binary is resolved and deal-pinned: OGN trades ~$13.51 into Sun Pharma's $14.00 all-cash offer, a ~$0.49 (3.7%) gross spread. The 2026-07-06 disclosure suit was mooted by 2026-07-17 supplemental proxy filings, clearing the path to…

Post-CHMP-rejection repair, not a new leg: shares have clawed back from the 2026-06-26 gap low of $8.67 to roughly $9.69 on the J1289 J-code going live 2026-07-01. The 2026-08-13 Q2 print is the whole trade consensus ~$11.6M net sales…

Sell-side discovery leg is spent: three Strong Buys with a $30.67 average against $28.68 (2026-07-17) leaves ~7% to consensus. The July 13 warrant redemption cleared the last dilution overhang, but the de-risking AFib endpoints are 2027…

Oral-GPCR platform narrative has matured from accelerating to extended after a ~3.5x run to an all-time high of $37.99; the ENDO 2026 visibility event came and went and the tape now sits in a catalyst vacuum, with the first real binary…

April denifanstat/acne breakout round-tripped to the $6.00 Series A offering floor; SGMT bases near $7 (last close $7.06, 2026-06-26) with no trend. Dermatology pivot (China NMPA acne NDA accepted Dec 2025, US IND due mid-2026) is real but…

A record short squeeze (~32% of float) and buyout speculation, now joined by sell-side PT hikes (Alliance Global $10→$25, Jul 17), have carried SLS to a $16 test and back to ~$13; the defining Phase 3 REGAL overall-survival readout stays…

Single-asset ivonescimab binary sitting $1.26 — above its $12.55 52-week low with going-concern language on the record. The narrative leg is dead but the funding question changed shape: co-CEO Duggan bought 3.81M shares at $13.12 on Jun 12…

The single event the name was priced around a July no-prior-auth formulary add for neffy came and went with no coverage win (2026-06-25 update). ARS pivoted to opex cuts ($248M guide) to defend 2027 breakeven as the stock sank and Leerink…

Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June…

Fallen-angel telehealth turnaround re-rating off lows: TDOC doubled from its $4.40 low to a fresh $9.78 52-week high on the Walmart Better Care distribution deal and BetterHelp's shift to insurance-reimbursed visits. But total revenue…

Clinical binary printed clean (2026-06-22: 100% milestone response N=12, zero treatment-related SAEs) but the next catalyst slipped to H1 2027 pivotal six-month interim AND FDA BLA-pathway feedback both guided to the first half of next…

FILSPARI's dual-indication ramp has fully re-rated the equity: at ~$56.71 (2026-07-17) TVTX trades at consensus PT ($52–58) and 4% under its 2026-06-25 ATH close of $59.03, having gone sideways for four weeks. The approval binary is spent;…

The Novo squeeze is fully round-tripped and the funding answer arrived on 2026-07-02: a $21.8M at-the-market program via Oppenheimer/Canaccord. At $2.42 (07-15) that is ~9M shares against ~16M outstanding the company will now sell stock…

June's volume-backed reclaim to $10.03 failed to extend $9.43 on Jul 17, -5.3% on the week, with short interest rising to 11.72% of float as shorts pressed the fade. Structure holds above the 50-DMA near $8.71, but nothing hard is dated…

Last large independent obesity asset and standing M&A target, but VK2735's VANQUISH pivotal topline isn't until 2027 a catalyst vacuum into a maturing, crowded GLP-1 theme, bridged only by a secondary 3Q26 maintenance-dose readout. Stock…

Busted-growth genomics name recovering off the −49% May guide-cut crash ($170→$32); sell-side ratcheting targets back up (Guggenheim $74 Jun 29, Piper $63 Jun 23), but the ~early-Aug Q2 ARR print vs the ~$3,300 baseline is the binary. A…

First annual same-store-sales decline in 22 years (Q1 2026 domestic SSS -8.7%) broke the compounder narrative; a ~50% relief bounce off the $116 low now runs into the July 29 Q2 print the binary on the guided H2 return to positive comps.…

X-TOLE2 Phase 3 win (2026-03-09, placebo-adjusted -42.7%, p≈6e-12) already de-risked azetukalner and re-rated XENE from the $40s to ~$71; the story is now maturing and range-bound into a procedural Q3 2026 NDA, with the next true binary…

Delisting binary resolved to the survive side: EGM passed 2026-06-29, Psyga psilocybin reverse-merger closed 2026-06-30, delinquent 20-F filed, Nasdaq listing held. ADS popped ~+90% intraday to ~$2.70 (~$6.4M cap). Now an illiquid…

IL-17/BAFF bispecific (tibulizumab) ran on a 2026-06-29 enrollment beat in HS and SSc, but that's execution de-risking, not efficacy the real binary is Q4 2026 TibuSHIELD topline. The RSI mid-80s spike faded ~8% into July with no hard…

MI450/Helios rack-scale plus EPYC agentic-CPU narrative drove ATHs near $561.80 (7/1), but the July target cluster ($600 BNP, $620 BofA, $725 high) is arriving into a falling tape 20-day MA lost 7/8, chip-led Nasdaq selloff 7/17, sentiment…

AI-server and enterprise-networking pivot is real at the theme level, but HPE's own chart broke: the record +25% Q2 FY26 blowoff (2026-06-02, ATH $64.25) fully round-tripped, the ~$48 pre-print shelf failed (last observed close $43.71 on…

HBM scarcity intact SK Hynix sees shortage into the next decade, Qualcomm/Hyundai auto deals signed 2026-07-16, US push to ban Chinese memory but the tape broke: SOXX −18.6% in July, worst month since 2008, and the $854.50 shelf failed. At…

Maturing AI-storage supercycle with sell-side still chasing: Wells Fargo upgrade to Overweight $1,100 (7/10) and Citi Street-high $1,240 (7/13). But the DRAM ETF is down ~30% and Seagate's Q4 FY26 print ~2026-07-22 is a binary about two…

The AI memory/storage supercycle that re-rated WDC has flipped from accelerating to breaking: the DRAM ETF is down ~30% in under a month (2026-07-13), CXMT's $10B Shanghai IPO (2026-07-15) plus SK Hynix/Samsung supply signals revived…

The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the…

Butterfly Embedded chip-licensing story got marquee validation Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but the…

Foundry-revival re-rating has unwound hard: INTC -31% in July vs TSM -15%, the ~$92 announcement shelf is gone, and SOXX just posted its worst month ever versus software. The 2026-07-23 Q2 print (18A yield, foundry loss, client CPU share)…

July killed the falling-wedge breakout: SOXX fell 18.6% (worst month since 2008) and 19.95% vs IGV (worst on record), Apple retook the market-cap crown, and Kimi K3 re-opened the compute-efficiency question. Earnings estimates held the…

June breakout fully round-tripped: ATH $386.46 (6/30) to $279.85 (7/17), now below the 50-DMA at $294.49. The tell is non-participation TSMC raised capex to $60-64B and ASML guided up twice on 7/15-16, and ONTO closed the week at its…

The data-center re-rating already failed: QCOM spiked to a 52-week high of $259.92 on the ~2026-06-24 Investor Day $15B-by-2029 guide, then gave back ~34% in 17 sessions to $171.78 as Hold downgrades and Apple modem-attrition math…

Q2 (7/16) beat on every line $40.20B rev +33.7% YoY, 67.7% GM, FY26 guide lifted to >40% growth yet the tape punished the capex raise to $60–64B and the 3–4pp 2nm margin dilution, driving the worst selloff since 2022 and a two-month low.…

Apple retook the world's-largest-company title from Nvidia on 2026-07-17 after a $1.45T two-month swing, powered by rotation out of AI semis plus a $30B Broadcom custom-silicon deal and reported AI-chip M&A hunting. The re-rate is now…

June memory/HBM semicap re-rating that carried ACLS to a $193.78 high has broken early-July profit-taking cut it ~15% below the June shelf and 50-day MA (~$160) to ~$135–143. FY2026 revenue still guided flat, so the remaining bull case…

Semiconductor-IP royalty re-accel is fundamentally intact (Q1 variable royalties +67% YoY, FY26 guide raised, fresh SiEngine/Li Auto auto wins), but the stock printed a $48.59 blowoff top (6/30) and reversed ~29% in a week, losing the ~$39…

Edge-AI silicon small-cap whose 2026-05-12 Q1 beat + Q2 guide-raise drove a parabolic to an $85.77 ATH (May 26), then a -12.4% distribution day (Jun 5). Catalyst is spent, no binary lands until the ~Aug Q2 print, and price sits above the…

Post-parabola OSAT laggard rebuilding under the $74-75 shelf after the 2026-06-16 TSMC 10-yr Arizona deal. Every catalyst since April has been sold (the beat -8.6%; the deal pop faded to -8.5% by 06-25), and the 2026-07-27 Q2 print is the…

AWS reacceleration (+28% YoY in Q1, 15-quarter high) has not converted into tape shares ~$245 vs the May high of $278.56, pinned on the 50-day with megacap flow rotating to IJR/IJH/RSP. KeyBanc lifted its target to $335 on 2026-07-16…

Post-parabola dormancy: the April–May "second-order AI power-semi" re-rate (~3x to $54.34) is fully realized, priced above the $30.50 consensus PT, with no fresh AOSL catalyst in five-plus weeks. Next binary is the ~early-August FY26-Q4…

Royalty re-rate leg has broken: HSBC cut to Hold with a $315 target (7/14) behind New Street's 6/18 Neutral, price has retraced through the the published invalidation level post-Computex base and the June low to a $295.18 reference (7/13),…

AI-compute test picks-&-shovels re-rate (Eclipse xPU handlers + Neon HBM inspection) is now a broad sell-side chase three PT raises in a month to $65–80 (TD Cowen $80, Baird $65, Stifel $70) with the stock near its $70.47 ATH after…

WFE-upcycle consumables re-rate now MATURING: after a +30% two-week run to ~$181 on the JSR/Inpria EUV cross-license and CNBC coverage, July sell-side is splitting Mizuho to $200 (07-01) vs Deutsche Bank Hold $155 (07-06), BMO $167 with…

AI-chip specialty/photonics differentiated vs TSM (not a dup), but Mubadala $1.91B block overhang caps upside until absorbed; clean entry is a 52w-high reclaim post-block, not now.

Automotive ADAS-silicon design-win story keeps improving on paper ($7.4B backlog, $25M radar order, ams OSRAM sensor buy) while the tape stays broken below the ~$4.00 50-day MA; TD Cowen's 2026-07-13 lift to a $4.50 Hold is a thaw, not a…

Process-control monopoly (~58% share, ~7.5x nearest rival) with an accelerating custom-silicon narrative, sold down in the worst semi month since 2008. Six analyst PT raises in eleven days but the July cluster ($255–274) sits well below…

US critical-minerals-sovereignty policy re-warming (Pentagon's $725M Energy Fuels stake, the Intel/US Steel government-equity template), but the lithium-price recovery leg is cold carbonate rolling over keeps LAC pinned to its $4.50 base.…

AI-data-center re-rating leg is unwinding round-tripped from the $105.91 May ATH to the ~$84 50-day EMA under an unrebutted J Capital short thesis and a 2026-07-13 TD Cowen PT cut to $90; only the cyclical MCU/industrial recovery (~93% of…

AI data-center power narrative still accelerating fundamentally (Enterprise Data ~2x YoY to $262.8M Q1; Q2 guide $890–910M, +35% YoY), but the tape bounced ~12% off the ~$1,200 shelf to ~$1,468 and now stalls at the 50-day into a binary…

Sympathy bid off the Micron-led memory supercycle and Russell 2000 inclusion floored the post-parabola markdown in the low-$20s, but the ~2026-07-28 Q2 print is now the binary: Everspin must show a non-casino datacenter/AI design win or…

Custom-silicon ASIC royalty story intact, but the AI-semi theme is mid-correction chips posted their worst month vs software on record (7/17) with money rotating into energy. Buying a falling sector with no confirmed higher low is the…

Beryllium critical-materials scarcity narrative still building, but the parabola cracked: a new ATH of $298.76 in early July gave way to a 5.6% reversal on 2026-07-07 to $247.20, now ~$258 and still ~9% above KeyBanc's $237 top target. The…

Analog/auto up-cycle re-rate in an "AI beyond Nvidia" jersey: estimates rising (TD Cowen $340, B of A $310 on 7/13; Citi $370) into a broken tape ~$266, down ~22% from the 5/27 ATH and ~12% below the $302 Street average, printing fresh…